Erik Sjögren, Assoc. Prof., Ph.D.

Principal Consultant & PBPK-QSP Platform Scientific Lead


  • Joined Pharmetheus in 2017, actively working in client projects
  • Expertise includes physiological based pharmacokinetic and biopharmaceutics modeling and simulation, clinical pharmacology, and pediatrics across therapeutic areas
  • Experience as Researcher at Uppsala University, Sweden, where he has a part-time position to perform research and supervise Ph.D. students. Previously, he worked as Acting Senior Lecturer at Uppsala University, Sweden and Postdoctoral Researcher at AstraZeneca Mölndal, Sweden
  • M.Sc. in Pharmaceutical Sciences (2004), Ph.D. in Pharmaceutical Sciences (2010), Associate Professor in Biopharmaceutics (2016) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South AsiaPhysiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children.Absorption, Bioavailability, and Immunogenicity after Subcutaneous Administration: Evaluation of a Subcutaneous Platform within the Open Systems Pharmacology frameworkPhysiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administrationPredicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modellingA platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology frameworkPhysiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive childrenOpen Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical SciencesMechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology frameworkPhysiologically-based pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) and recombinant FIX (rFIX) to characterize extravasation and binding to type IV collagen